Adults with type-2 diabetes using the investigational drug survodutid achieved a weight loss of up to 13.1% after 76 weeks in a phase-3 clinical trial, according to trial data presented at the European Association for the Study of Diabetes and published in the New England Journal of Medicine. Boehringer Ingelheim and Zealand Pharma developed the substance tested in the SYNCHRONIZE-2 trial, where the control group receiving a placebo recorded a weight reduction of 3.1% over the same period.
Survodutid Participants Lose up to 13.1% Body Weight
The SYNCHRONIZE-2 study evaluated adults with overweight or obesity alongside type-2 diabetes over a 76-week treatment window. When measured by the efficacy estimand, participants taking survodutid lost up to 13.1% of their baseline body weight. Boehringer Ingelheim reported that 79.3% of trial participants in the survodutid group achieved a clinically relevant weight loss of at least 5%. By comparison, only 32.7% of participants in the placebo group reached that threshold.
Those figures contrast with results from an earlier trial released in April involving participants without diabetes, where patients on survodutid achieved a weight loss of 16.6%. Market observers noted that the divergence in efficacy between diabetic and non-diabetic cohorts influenced investor reactions. Following the data publication, shares of Zealand Pharma dropped between 9% and 10% in early trading in Copenhagen.
Survodutid Reduces Blood Glucose Levels and Waist Size
Beyond weight reduction, trial data demonstrated measurable improvements in metabolic parameters for patients managing type-2 diabetes. Participants taking survodutid experienced a drop in long-term blood glucose levels, with HbA1c decreasing by up to 1.21 percentage points from a baseline average of 7.4%. The placebo group recorded an HbA1c reduction of just 0.03 percentage points.
Waist circumference measurements also reflected physical changes across the study cohorts. Participants in the survodutid arm reduced their waist size by an average of 11.1 centimeters. Participants in the placebo group saw a reduction of 3.5 centimeters. Boehringer Ingelheim additionally noted improved insulin sensitivity among the trial participants receiving the active compound.
Gastrointestinal Side Effects Cause Treatment Discontinuations
The therapeutic benefits observed in the trial were accompanied by a notable rate of adverse events leading to treatment discontinuation. Gastrointestinal side effects caused 18% of participants in the survodutid group to stop taking the medication. In contrast, only 1.2% of participants in the placebo group discontinued treatment due to similar gastrointestinal complaints.
Survodutid remains unapproved by regulatory authorities. The definitive efficacy and safety profile of the drug has not yet been established for commercial use, and Boehringer Ingelheim has additional steps remaining in the regulatory review process.
When and Where SYNCHRONIZE-2 Results Were Published?
- When and where were the SYNCHRONIZE-2 trial results made public? The findings were presented on October 1, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes and published simultaneously in the New England Journal of Medicine.
- What companies are developing survodutid? The investigational substance is jointly developed by Boehringer Ingelheim and Zealand Pharma.
- What is the regulatory status of survodutid? The drug is currently investigational and holds no commercial approval from health regulators.
Keep reading